Champions Oncology, Inc. reported fiscal 2026 revenue of $59.43M, up 4.4% from $56.94M a year earlier, while net loss was ($1.18M) versus net income of $4.7M in 2025 and diluted EPS fell to ($0.08) from $0.33— 10-K Summary.
Financial Highlights
| MetricCurrent yearPrior yearYoY change | Revenue¹$59.43M$56.94M4.4% | Net income²($1.18M)$4.7M(125%) | Diluted EPS³($0.08)$0.33(124.2%) |
¹ Reported as “Oncology revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Net income (loss) per common share outstanding”.
Business Highlights
- Revenue growth of 4.4% was driven by higher pharmacology services and conversion of delayed studies.
- Data license sales of TOS declined after a large 2025 deal did not repeat; the customer base broadened with smaller licenses.
- R&D spending rose about 33% and the company increased investment in its data platform, sequencing, lab costs and staffing to expand Datacenter/Lumin capabilities.
- Cost of oncology revenue increased 8.8% due in part to outsourced radiopharma work; radiopharma activities were brought in‑house in FY2026 to reduce future costs.
- Sales, marketing and G&A expenses grew roughly 20–24% as the company expanded its commercial team, IT and leadership to support growth.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.